Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
c-TRAK TN ctDNA-guided pembrolizumab trial in early triple-negative breast cancer
2017-000508-92Phase 2Unknown
- Sponsor
- The Institute of Cancer Research
- Start
- May 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in triple-negative breast cancer (TNBC) (2 cohorts), sponsored by The Institute of Cancer Research. Primary endpoints: Positive ctDNA detection by 12 months and Positive ctDNA detection by 24 months. Status: unknown.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2017-000508-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000508-92.